DESTINY-Breast12: enhancing outcomes for HR+/HER2+ patients with brain metastases

Dr O'Brien on Breast Cancer Research in Patients With HER2+ Brain MetastasesПодробнее

DESTINY-Breast12 Intracranial activity of TDXd in HER2-positive Patients with brain metastasesПодробнее

Exploring Abemaciclib for the Treatment of Brain Metastases in HR+/HER2- Breast CancerПодробнее

Therapeutic landscape for patients with HER2-positive breast cancer with active brain metastasesПодробнее

HER2CLIMB Study Shows Efficacy in HER2 Breast Cancer With Brain MetastasesПодробнее

Breast Cancer ESMO 2024 Highlights: Key Studies Discussed NATALEE, KEYNOTE 522, DESTINY-Breast12Подробнее

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancerПодробнее

DESTINY-Breast12: T-DXd in patients with HER2+/HR- breast cancer with brain metastasisПодробнее

HER2CLIMB: tucatinib efficacious against brain metastases in patients with HER2+ breast cancerПодробнее

Study of Neratinib for Patients with HER2-Positive Breast Cancer with Brain MetastasesПодробнее

A New Treatment for Breast Cancer Patients with Brain Metastases: An Interview with Dr. Nancy LinПодробнее

Current and future HER2+, HR- metastatic breast cancer treatment approachesПодробнее

Trastuzumab deruxtecan in patients with breast cancer and brain metastases in DESTINY-Breast01Подробнее

Targeting HER2 in Breast Cancer Patients With Brain MetastasesПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

The evolution of HER2 targeting in metastatic breast breast cancerПодробнее

Brain metastases in HER2+ breast cancerПодробнее

HER2+ Breast Cancer: Brain Metastasis Prevalence & Later-Line TherapyПодробнее

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer ptsПодробнее